Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Regulation of Vascular Smooth Muscle Tone by Adipose-Derived Contracting Factor

Regulation of Vascular Smooth Muscle Tone by Adipose-Derived Contracting Factor

  • Matthias R. Meyer, 
  • Natalie C. Fredette, 
  • Matthias Barton, 
  • Eric R. Prossnitz


Obesity and arterial hypertension, important risk factors for atherosclerosis and coronary artery disease, are characterized by an increase in vascular tone. While obesity is known to augment vasoconstrictor prostanoid activity in endothelial cells, less is known about factors released from fat tissue surrounding arteries (perivascular adipose). Using lean controls and mice with either monogenic or diet-induced obesity, we set out to determine whether and through which pathways perivascular adipose affects vascular tone. We unexpectedly found that in the aorta of obese mice, perivascular adipose potentiates vascular contractility to serotonin and phenylephrine, indicating activity of a factor generated by perivascular adipose, which we designated “adipose-derived contracting factor” (ADCF). Inhibition of cyclooxygenase (COX) fully prevented ADCF-mediated contractions, whereas COX-1 or COX-2-selective inhibition was only partially effective. By contrast, inhibition of superoxide anions, NO synthase, or endothelin receptors had no effect on ADCF activity. Perivascular adipose as a source of COX-derived ADCF was further confirmed by detecting increased thromboxane A2 formation from perivascular adipose-replete aortae from obese mice. Taken together, this study identifies perivascular adipose as a novel regulator of arterial vasoconstriction through the release of COX-derived ADCF. Excessive ADCF activity in perivascular fat under obese conditions likely contributes to increased vascular tone by antagonizing vasodilation. ADCF may thus propagate obesity-dependent hypertension and the associated increased risk in coronary artery disease, potentially representing a novel therapeutic target.


There is growing evidence that perivascular adipose (commonly referred to as perivascular adipose tissue, PVAT), a specific visceral fat compartment that surrounds blood vessels with no fascial layer separating it from the vascular wall, may regulate vascular function through paracrine mechanisms, only some of which have been identified [1][4]. Perivascular adipose represents a source of relaxing factors, such as adiponectin, angiotensin 1–7, hydrogen sulfide, and adipose-derived relaxing factor (ADRF) [1][4]. On the contrary, little is known about perivascular adipose-derived contractile factors. Stimulated superoxide formation in perivascular adipose, for example, may reduce the bioactivity of the endothelial vasodilator NO [5], thereby indirectly mediating an increase in vascular tone. Whether perivascular adipose releases contracting factors that act directly on vascular smooth muscle has not yet been addressed.

Under healthy conditions, perivascular adipose exerts anti-contractile activity [6][9], which is lost in obesity despite concomitant increases in perivascular adipose mass [8][10]. This strongly suggests the existence of (yet unidentified) counteracting vasoconstricting mechanisms that become activated when obesity develops, consistent with the notion that increased perivascular adipose mass is associated with arterial hypertension in obese patients [11]. Similarly, we have previously reported that vasoconstriction due to endothelial cell-derived, cyclooxygenase (COX)-dependent prostanoid formation is enhanced in diet-induced and monogenic models of obesity [12][14]. However, in these previous studies, perivascular adipose had been removed, excluding the possibility of examining its direct effects on vascular tone.

To address whether perivascular adipose is a source of endogenous vasoconstrictors that might alter the balance between relaxing and contracting factors [15], for the present study we employed not only a diet-induced obesity (DIO) model, but also a novel model of monogenic visceral obesity, the G protein-coupled estrogen receptor (GPER)-deficient mouse [16][20]. GPER is a 7-transmembrane G protein-coupled receptor superfamily member that has been shown to mediate many of the rapid physiological and cellular effects of estrogen [16], [17], in conjunction with the classical nuclear estrogen receptors [17]. Animals of both obesity models are normotensive [14], [21], making them particularly attractive to study functional vascular changes associated with the obesity phenotype independent of blood pressure. Similar to changes typically present in animal models of obesity [12], [13], [22] and obese humans [23][26], the GPER0 obesity model is characterized by visceral obesity [18], [19], [27], dyslipidemia [27], insulin resistance [27] as well as enhanced responses to endothelium-derived vasoconstrictor prostanoids and to endothelin-1 [14], [28]. In view of these findings and given our recent observation that both the GPER0 and DIO models exhibit excessive perivascular adipose surrounding the thoracic aorta, we hypothesized that perivascular adipose-derived vasoactive factors might contribute to the regulation of vascular tone in these animals.

The results presented in the present study unexpectedly reveal that perivascular adipose controls arterial smooth muscle tone by releasing an “adipose-derived contracting factor” (ADCF) formed by COX that becomes functionally relevant in obesity. Consistent with a source of COX-derived lipid vasoconstrictors, perivascular adipose releases thromboxane A2 in lean mice, and to a greater extent in monogenetic and diet-induced obesity that is likely sufficient to counteract endogenous vasodilator activity.

Materials and Methods

Animal models

C57Bl6 (Harlan Laboratories, Indianapolis, IN; 12 months of age) and monogenic obese GPER-deficient (GPER0) mice (originally provided by Jan S. Rosenbaum, Proctor & Gamble, Cincinnati, OH, [20]) were bred and housed at the animal research facility of the University of New Mexico Health Sciences Center as described [14], [28]. Only male animals were used to exclude vasoactive and metabolic effects of estrogens [17]. Animals had access to standard rodent chow (16% of total kcal from fat: Teklad Diet 2020SX; Harlan Laboratories) and water ad libitum. In a subset of C57Bl6 mice (6 weeks of age), obesity was induced using a 24 week high-fat diet protocol (42% of total kcal from fat: Teklad Diet TD.09821) [29]. All procedures were approved by the University of New Mexico Institutional Animal Care and Use Committee and carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Blood pressure measurements

Systolic and diastolic blood pressure were measured in conscious mice using a noninvasive volume-pressure monitoring/recording system (CODA-6, Kent Scientific, Torrington, CT), which correlates well with invasive measurements [30]. Following a training period of 5–7 days, means of 16 measurements recorded on 5–8 days were averaged for each mouse and used for subsequent data analysis.

Isolated vessel preparation and experimental setup

Animals were euthanized by intraperitoneal injection of sodium pentobarbital (2.2 mg/g BW). The thoracic aorta with surrounding perivascular adipose was immediately excised and placed in cold (4°C) physiological saline solution (PSS, composition in mmol/L: 129.8 NaCl, 5.4 KCl, 0.83 MgSO4, 0.43 NaH2PO4, 19 NaHCO3, 1.8 CaCl2, and 5.5 glucose; pH 7.4). Isolated thoracic aortae were cut into 4 mm long segments, which were divided into two 2 mm long rings, where perivascular adipose was either carefully removed or left intact. This allowed for direct study of the effects of perivascular adipose within the same segment of one thoracic aorta. Vessels were transferred to an organ chamber of a Mulvany-Halpern myograph [31] and mounted onto two 200 µm pins, one connected to a force transducer and the other to a micropositioner (620M multi-channel myograph, Danish Myo Technology, Aarhus, Denmark) as described [14].

Vascular function analysis

After equilibrating in PSS (37°C; oxygenated with 21% O2, 5% CO2, and balanced N2; pH 7.4 [32]) for 30 min, rings were progressively stretched to the optimal passive tension for generating force during isometric contraction (19 mN) [14]. Rings were allowed to equilibrate for 45 min, and repeatedly exposed to KCl (PSS with equimolar substitution of 60 mmol/L potassium for sodium) until a stable response was achieved. Rings that developed less than 9.81 mN of force were discarded. Where indicated, rings were incubated with either the cyclooxygenase (COX) inhibitor meclofenamate (1 µmol/L), the COX-1-selective inhibitor SC-560 (300 nmol/L), the COX-2-selective inhibitor CAY10404 (100 nmol/L), the NO synthase inhibitor L-NG-nitroarginine methyl ester (L-NAME, 300 µmol/L), the superoxide dismutase mimetic 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine (Tempol, 100 µmol/L), or the highly selective ETA endothelin receptor antagonist BQ-123 (100 nmol/L) [33] for 30 min prior to exposure to agonists. Subsequently, concentration-response curves to serotonin (1 nmol/L – 10 µmol/L) or phenylephrine (1 nmol/L – 1 µmol/L) were obtained.

Quantitation of thromboxane A2 release by perivascular adipose

The ex vivo formation of thromboxane A2 from perivascular adipose was assayed using a competitive enzyme immunoassay (EIA) as described [34]. Briefly, after incubating neighboring aortic rings with and without perivascular adipose with the highest serotonin concentration (10 µmol/L) for 3 min, the bath fluid (5 mL) was snap-frozen in liquid nitrogen and stored at −80°C for subsequent analysis. Thromboxane A2 production was measured by determining the concentration of its hydrolyzed metabolite, thromboxane B2 [35], using a competitive EIA kit according to the manufacturer's instructions (Cayman Chemical, Ann Arbor, MI, USA). In order to quantify thromboxane production specifically originating from perivascular adipose, individual aortic segments (4 mm in length) were divided into two equally sized rings, and thromboxane production was determined in one half with perivascular adipose removed. This value was subtracted from that measured in the other half with intact perivascular adipose, and values were normalized to tissue dry weight.

Quantitation of perivascular adipose steady-state mRNA expression levels

Aortic perivascular adipose (30mg) was snap-frozen in liquid nitrogen and disrupted using a rotor-stator homogenizer. Total RNA was extracted using the silica-based RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, CA, USA). RNA was reverse transcribed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). PCR was performed using SYBR Green-based detection of amplified gene-specific cDNA fragments on a 7500 FAST real-time PCR System (Applied Biosystems) using the sets of primers given in Table S1, with specificity confirmed by melting curve analysis. Gene expression was calculated based on the 2−ΔΔCT method [36]. GAPDH served as a housekeeping control and showed identical CT values between groups.

Substances and drugs

Meclofenamate, SC-560, CAY10404 and L-NAME were from Cayman Chemical. Serotonin was from MP Biomedicals (Solon, OH, USA), and Tempol from Tocris Bioscience (Minneapolis, MN, USA). All other drugs were from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions were prepared according to the manufacturer's instructions, and diluted in PSS to the required concentrations before use. Concentrations are expressed as final molar concentration in the myograph chamber.

Data calculation and statistical analyses

Contraction is given as the percentage of contraction relative to 60 mM KCl [14]. Maximal responses, area under the curve (AUC) and EC50 values (expressed as pD2) of the concentration-response curves were calculated by curve fitting as described by deLean et al. [37], using FitLab® software run in MatLab 5.0 on a Macintosh computer. Where no plateau was reached, AUC was calculated using the trapezoidal rule approximation in Prism (version 5.0 for Macintosh, GraphPad Software, San Diego, CA, USA) [38]. Parametric data were analyzed using the two-tailed Student's t test or by two-way ANOVA followed by Bonferroni's post-hoc test as appropriate; non-parametric data were analyzed using the Mann-Whitney U test (Prism version 5.0 for Macintosh). All data are expressed as mean ± SEM. A p value of <0.05 was considered significant.


Monogenic obesity increases perivascular adipose mass

In preliminary experiments with the GPER0 model of monogenic obesity [18], [19], we observed a marked increase in perivascular adipose mass compared with WT controls (3.6-fold increase, adipose mass normalized to tibial length, 8.3±1.2 mg/mm vs. 2.3±0.4 mg/mm, n = 5–8, p<0.01 vs. control, Figure 1A). By contrast, the increase in perigonadal fat mass in GPER0 mice was less pronounced (1.6-fold, normalized to tibial length, 108.6±7.4 vs. 70.8±9.4 mg/mm, n = 8–9, p<0.01 vs. control, Figure 1B). The increase in visceral fat was associated with a significant increase in body weight (41.3±1.2 vs. 36.2±1.2 g, n = 19, p<0.01 vs. lean WT control, Figure 1C), whereas tibial length as a measure of body length was identical in GPER0 and WT control animals (18.6±0.1 mm, n = 5). Obesity (body weight and perivascular adipose) was already present in GPER0 animals at 3 months of age (Figure S1), but by 12 months of age had progressed much further in adult animals (Figure 1). Therefore, 12 month-old animals were selected for vascular function analyses. Despite excessive visceral fat accumulation [18], [27], blood pressure in GPER0 mice remained unchanged compared to controls (systolic, 119.0±0.8 vs. 121.3±1.7 mmHg; diastolic, 90.2±1.3 vs. 89.3±1.9 mmHg; n = 6–7, Figure 1D), consistent with normotensive blood pressure levels measured in the DIO model [21].

Figure 1. Perivascular adipose and perigonadal fat mass, body weight and blood pressure in monogenic obesity (GPER0).

A, Mass and macroscopic difference in the quantity of perivascular adipose (PVAT) surrounding the aorta (a, Aortic arch; b, Thoracic aorta; c, Abdominal aorta) of obese (GPER0, n = 5) and lean WT control mice (CTL, n = 8). B, Perigonadal fat weight (CTL, n = 8; GPER0, n = 9); C, body weight (n = 19/group); D, systolic and diastolic blood pressure levels in obese (GPER0, , n = 7) and lean WT mice (CTL, , n = 6). Fat weights are normalized to tibial length. A–C: open bars, lean WT control (CTL); solid bars, monogenic obesity (GPER0). *p<0.01 vs. control.

Murine perivascular adipose from the aorta is highly similar to brown adipose tissue and resistant to obesity-induced inflammation [39]. Accordingly, steady-state gene expression levels of the pro-inflammatory tumor necrosis factor (TNF)-α and leptin genes in perivascular adipose were unaffected by GPER deficiency (Table 1). We also found no change in peroxisome proliferator activated receptor PPARγ expression (Table 1). Of note, expression levels of adiponectin (which has been designated a perivascular adipose-derived relaxing factor [ADRF] in humans [9], but not in mice [8]), was reduced 2.4-fold in perivascular adipose from GPER0 mice (Table 1).

Table 1. Quantitative measurements of adipocyte-related gene expression in aortic perivascular adipose from GPER0 and control mice.

Perivascular adipose potentiates serotonin-induced contractions in monogenic obesity

We hypothesized that perivascular adipose might alter agonist-stimulated contractility, which is enhanced in obesity [12][14]. In perivascular adipose-intact aortic rings of mice with monogenic obesity (GPER0), maximal contractions to serotonin (relative to 60 mmol/L KCl) were enhanced (1.3-fold, 93.8±2.8 vs. 73.2±6.1%KCl, n = 6–7, p<0.01 vs. control, Figure 2). Removal of perivascular adipose markedly reduced maximal serotonin-induced contractions in rings from GPER0 obese mice (47% inhibition, from 93.8±2.8 to 54.4±7.0%KCl, n = 6–7, p<0.001 vs. rings without adipose) but not in lean WT controls (73.2±6.1 vs. 67.4±6.0%KCl, n = 6–7, p = n.s. vs. rings without adipose, Figure 2). Furthermore, contractions to serotonin in rings without perivascular adipose were not different between mice with monogenic obesity and WT controls (Figure 2). Moreover, KCl induced similar responses in rings with and without perivascular adipose of both GPER0 mice (16.1±0.7 vs. 16.3±0.8 mN) and controls (16.4±0.5 vs. 16.0±0.5 mN).

Figure 2. Potentiating effect of perivascular adipose on serotonin-induced contractions in mice with monogenic obesity.

Aortic rings with and without perivascular adipose (PVAT) from monogenetic obese GPER0 or lean WT (control) mice were exposed to increasing concentrations of serotonin. Inset: Area under the curve (AUC) of the concentration-response curves is expressed as arbitrary units (AU). , control without PVAT (n = 7); , control with PVAT (n = 6); , GPER0 without PVAT (n = 6); , GPER0 with PVAT (n = 7). *p<0.05 vs. aortic rings without perivascular adipose; †p<0.05 vs. control.

In lean WT controls, the sensitivity of serotonin-induced contractions was slightly but significantly lower when perivascular adipose was present (pD2 6.40±0.12 vs. 6.72±0.06 umol/L, n = 6–7, p<0.05 vs. rings without perivascular adipose), indicative of an anti-contractile effect of perivascular adipose in lean animals (Figure 2). These findings are consistent with previous observations in the murine aorta [40], whereas perivascular adipose-mediated anti-contractile effects are substantially greater in rats [7], [8]. However, our finding of potentiation of contractions by perivascular adipose in mice with monogenic obesity were the first suggestion that a contracting factor derived from perivascular adipose increases vascular tone by potentiating serotonin-induced contractions. Due to its site of origin this factor was termed “adipose-derived contracting factor” (ADCF).

Functional characterization of adipose-derived contracting factor (ADCF)

We have previously reported that obesity activates the formation of cyclooxygenase (COX)-derived vasoconstrictor prostanoids in endothelial cells [12][14]. Given that adipocytes as well as other cell types present in adipose express COX [41], [42], we hypothesized that the ADCF-dependent potentiation of serotonin-induced contractions might be mediated by COX products. Gene expression analyses detected both COX-1 and COX-2 isoforms in perivascular adipose, with steady-state mRNA expression levels of COX-1 being about 80-fold higher than those of COX-2 (Table 2). Monogenic obesity had no effect on mRNA expression levels (Table 2). Since a lack of change in gene or even protein expression does not rule out changes in enzyme activity, we determined whether COX-derived vasoconstrictor prostanoids contribute to the potentiation of serotonin-induced contractions by treating perivascular adipose-intact rings with the isoform-nonselective COX-inhibitor meclofenamate (1 µmol/L for 30 min). In aortic rings of mice with monogenic obesity, inhibition of COX completely prevented perivascular adipose-dependent contractile effects, reducing serotonin-induced contractions by 41% (from 93.8±2.8 to 54.9±13%KCl, n = 5–7, p<0.01 vs. untreated rings, Figure 3). By contrast, in lean WT controls, COX inhibition had no effect on contractions to serotonin (67.4±3.5 vs. 73.2±6.1%KCl, n = 6–7, p = n.s. vs. untreated rings, Figure 3).

Figure 3. Cyclooxygenase inhibition prevents perivascular adipose-dependent potentiation of contractions to serotonin in monogenic obesity.

Aortic rings with perivascular adipose (PVAT) from monogenic obese GPER0 mice or lean WT (control) mice were pretreated with the cyclooxygenase inhibitor meclofenamate (Meclo, 1 µmol/L) prior to stimulation with increasing concentrations of serotonin. Inset: Area under the curve (AUC) of concentration-response curves is expressed as arbitrary units (AU). , control, untreated (n = 6); , control, meclofenamate (n = 7); , GPER0, untreated (n = 7); GPER0, meclofenamate (n = 6). *P<0.001 vs. untreated vascular rings; †p<0.05 vs. control.

Table 2. Effect of obesity on gene expression of cyclooxygenase (COX)-1 and COX-2 isoforms in aortic perivascular adipose.

To exclude an effect specific to serotonin as an agonist, parallel experiments were performed with the predominantly α1-adrenergic agonist phenylephrine. As with serotonin-induced contractions, phenylephrine-induced contractions were equally reduced by COX inhibition in aortic rings with intact perivascular adipose from obese mice (41% inhibition of the 1 µM phenylephrine response, from 77.3±2.1 to 46.0±3.8%KCl, n = 6, p<0.001 vs. untreated rings), but not in lean controls (Figure S2), indicating that ADCF becomes activated in obesity and augments contractions regardless of the contractile agonist.

To further delineate which COX isoform mediates the ADCF effect in serotonin-induced contractions, we performed experiments using either the COX-1-selective inhibitor SC-560 or the COX-2-selective inhibitor CAY10404. While meclofenamate fully prevented ADCF activity (Figure 3, right panel), each isoform-selective COX inhibitor was only partially effective (Figure S3). By contrast, SC-560 and CAY10404 had no effect on rings from healthy, lean mice (Figure S3).

In order to rule out the possible contribution of additional factors in the adipose-mediated potentiation of contraction, experiments were performed to assess other vasoconstrictor pathways and targets known to play a role in vascular disease development and obesity, such as endothelin-1 [43] and reactive oxygen species [22], [25], [44]. None of the following inhibitors had an effect on ADCF activity during serotonin-induced contractions in rings with perivascular adipose from obese mice: the NO synthase inhibitor L-NAME, as uncoupled NO synthase can produce vasoconstricting superoxide [45] (93.1±2.9 vs. 93.8±2.8%KCl, p = n.s.), the superoxide scavenger and superoxide dismutase mimetic Tempol [46] (89.5±2.9 vs. 93.8±2.8%KCl, p = n.s.) or the highly ETA-selective endothelin receptor antagonist BQ-123 [33] (88.4±2.6 vs. 93.8±2.8%KCl, p = n.s.). These results exclude a contribution of these pathways in the ADCF responses observed and thus further corroborate the nature of ADCF as a COX-derived vasoconstrictor prostanoid in monogenetic obesity.

Effect of perivascular adipose on vascular tone in diet-induced obesity

In order to rule out extraneous effects of GPER deficiency by solely using the monogenic GPER0 model of obesity, we also characterized the effect of perivascular adipose on contractions in the well-established C57BL6 model of diet-induced obesity (DIO) [29]. Similar to the monogenic GPER0 obesity model, DIO mice showed an increase in perivascular adipose mass (2-fold, adipose mass normalized to tibial length, 7.0±0.7 vs. 3.5±0.3 mg/mm, n =  6–10, p<0.01 vs. control), perigonadal fat mass (1.6-fold, normalized to tibial length, 141.3±5.4 vs. 87.4±10.6 mg/mm, n = 6–10, p<0.001 vs. control) and body weight (42.9±1.0 vs. 35.9±1.6 g, n = 9–12, p<0.01 vs. control). Consistent with the ADCF-mediated potentiation of serotonin-induced contractions in monogenic obesity (Figure 2), contractions in perivascular adipose-intact rings were increased by 29% in DIO mice (90.1±4.5 vs. 69.9±5.1%KCl, n = 5–7, p<0.01 vs. rings without perivascular adipose, Figure 4). The presence of perivascular adipose had no effect on contractions in age-matched lean controls (80.2±5.1 vs. 78.3±3.8%KCl, n = 6, p = n.s. vs. rings without perivascular adipose, Figure 4). Of note, KCl-induced contractions in rings with and without perivascular adipose were similar in DIO (14.3±0.5 vs. 13.8±1.1 mN) and control mice (14.2±0.3 vs. 13.9±0.3 mN).

Figure 4. Effect of perivascular adipose on serotonin-induced contractions in mice with diet-induced obesity.

Aortic rings with and without perivascular adipose (PVAT) from WT mice with diet-induced obesity (DIO) or lean WT mice (control) mice were exposed to increasing concentrations of serotonin. DIO animals were fed a high-fat diet for 24 weeks and compared to age-matched mice fed a standard chow (control). Inset: Area under the curve (AUC) is expressed as arbitrary units (AU). , control, without PVAT (n = 6); , control, with PVAT (n = 6); , DIO, without PVAT (n = 5); , DIO, with PVAT (n = 7). *p<0.05 vs. aortic rings without perivascular adipose; †p<0.05 vs. control.

We next determined the effect of the COX inhibitor meclofenamate on the ADCF response with serotonin-mediated contractions in DIO mice. Incubation with meclofenamate markedly reduced contractions to levels that were even below those of untreated controls (62.2±5.1 vs. 90.1±4.5%KCl, n = 5–7, p<0.01 vs. untreated rings, Figure 5). Meclofenamate had no effect on rings from lean mice (82.6±5.3 vs. 80.2±5.1%KCl, n = 4–6, p = n.s. vs. untreated rings, Figure 5). Similar to the results obtained with the monogenic obesity model (Figure S3), the COX-1-selective and COX-2-selective inhibitors each only partially attenuated the ADCF effect in DIO mice, but had no effect in lean controls (Figure S4). As in monogenic obesity, the ADCF effect on contractions to phenylephrine in DIO mice was also reduced considerably by nonselective COX inhibition (20% inhibition of the 1 µM phenylephrine response, from 91.4±2.4 to 74.1±3.8%KCl, n = 6, p<0.01 vs. untreated rings, Figure S2). However, there was no difference in perivascular mRNA expression levels of COX-1 or COX-2 between DIO mice and lean controls (Table 2). The results of these experiments provide further evidence that a COX-derived ADCF becomes functionally active in obesity, regardless of the cause (i.e. primary obesity due to gene mutation or secondary obesity due to excessive caloric intake). Thus, ADCF activation appears to represent a general functional change that may be due to conditions, such as obesity, that are, at least in part, associated with an increase in overall and/or perivascular adipose mass.

Figure 5. Cyclooxygenase inhibition prevents perivascular adipose-dependent potentiation of contractions to serotonin in diet-induced obesity.

Aortic rings with perivascular adipose (PVAT) from WT mice with diet-induced obesity (DIO) or lean WT mice (control) mice were exposed to increasing concentrations of serotonin in the presence or absence of the cyclooxygenase inhibitor meclofenamate (Meclo, 1 µmol/L). DIO animals were fed a high-fat diet for 24 weeks and compared to age-matched mice fed a standard chow (control). Inset: Area under the curve (AUC) is expressed as arbitrary units (AU). , control, untreated (n = 6); control, meclofenamate (n = 4); , DIO, untreated (n = 7); , DIO, meclofenamate (n = 5). *p<0.001 vs. untreated vascular rings; †p<0.05 vs. control.

Chemical nature of the ADCF activity released from perivascular adipose

The results of the functional experiments obtained in mice with monogenic obesity and DIO strongly suggested that the ADCF activity released from perivascular adipose might consist of lipid-based vasoconstrictor prostanoids. Using the bioassay as a source of adipose-derived factors, we determined the generation of COX-dependent products in perivascular adipose by measuring the amount of the predominant COX-derived vasoconstrictor prostanoid thromboxane A2 [15], [42] released in response to serotonin-mediated contractions. Surprisingly, thromboxane A2 was produced by the perivascular adipose of lean control mice (Figure 6). However, both monogenic obesity and DIO were associated with greatly increased thromboxane A2 production in adipose (241% and 85% increases, respectively, normalized to perivascular adipose weight, n = 4–6, p<0.05 vs. control, Figure 6). These findings are compatible with the concept that perivascular adipose-released ADCF activity consists of COX-derived vasoconstrictor prostanoids, including thromboxane A2. ADCF may act via paracrine effects on vascular smooth muscle to increase vascular tone through COX-derived contracting factors such as thromboxane A2, prostaglandin D2, prostaglandin E2, prostaglandin F2α, prostaglandin H2, or prostaglandin I2 (prostacyclin) [15], [47].

Figure 6. Production of thromboxane A2 by perivascular adipose.

Thromboxane A2 release was stimulated during serotonin-dependent contractions and measured as its hydrolyzed metabolite thromboxane B2. Measurements in vascular rings without perivascular adipose were subtracted from rings with perivascular adipose and normalized to dry weight to reveal functional changes in perivascular adipose. Measurements were performed in perivascular adipose from mice with monogenic obesity (GPER0, left panel, solid bar, n = 4) or from mice with diet-induced obesity (DIO, right panel, solid bar, n = 5). Age-matched WT mice fed a regular chow served as controls (CTL, open bars, n = 6, mean thromboxane A2 production: 15.1±3.8 pg/mg). *p<0.05 vs. CTL.


A role for perivascular adipose as a source of neurohumoral regulators was first proposed more than 20 years ago, when Soltis and Cassis reported an indirect vasodilator activity [6]. Subsequent studies have shown that perivascular adipose releases several adipokines capable of reducing vascular tone under healthy conditions [1][4], [7][9]. Using models of monogenic obesity [14] and DIO [12], [13], we have previously reported increased cyclooxygenase (COX)-dependent endothelial prostanoid formation in arterial rings devoid of perivascular adipose. Abnormal COX-mediated vasoconstriction has also been confirmed in obese humans [25], [26]. The role of perivascular adipose in the regulation of vasoconstrictor tone, both under basal conditions as well as in obesity, is less clear [48]. Previous observations that the anti-contractile activity of perivascular adipose [6][9] is lost in obesity despite an increase in net perivascular adipose mass [8][10] strongly suggested the existence of (yet unidentified) counteracting vasoconstrictor mechanisms that become activated only as obesity develops. The present study now identifies perivascular adipose as a mediator of increased arterial smooth muscle tone through the release of COX-derived vasoconstrictor prostanoids, which we have designated “adipose-derived contracting factor” (ADCF). We also found that perivascular adipose releases the COX-derived vasoconstrictor thromboxane A2 in response to serotonin in healthy, lean mice. Of note, thromboxane A2 formation from perivascular adipose is greatly enhanced both in primary (genetic) GPER0 obesity [18], [19], and secondary obesity following excess caloric intake [29]. The results indicate that perivascular adipose is a novel source of COX-derived vasoconstrictor activity that increases vascular smooth muscle tone, demonstrating enhanced effects in obesity.

Since the 1930s, tissue has been used to characterize and identify vasoactive factors controlling smooth muscle tone [49], [50]. Similar to the COX-dependent ADCF activity identified from perivascular adipose reported in the present study, a smooth muscle vasoconstrictor activity released from rat lungs [49], [50] was later shown to be sensitive to COX inhibition [51][53]. Because the “active non-histamine material” [50] also contracted arterial blood vessels, Vane and coworkers renamed this activity “rabbit aortic contracting substance” (RCS) [53], [54]. RCS was subsequently shown to be derived from a microsomal enzyme [55] identical to COX and to evoke contraction predominantly through the prostaglandin H2 derivative, thromboxane A2 [56], which was also found to potently activate platelets [35]. Shortly thereafter, prostaglandin H2/thromboxane A2 were identified as COX-derived endothelial cell prostanoids mediating smooth muscle contraction via paracrine mechanisms (endothelium-derived contracting factors, EDCF) [15], [47], [57]. In the present study, we now demonstrate for the first time that COX-derived constrictor activity mediating vascular smooth muscle contraction is also produced by perivascular adipose.

It has previously been shown that, when a patient becomes obese, perivascular adipose loses its anti-contractile activity normally present in small gluteal arteries [9]. Similar results have been reported in mesenteric arteries with the onset of monogenic obesity in mice [8], whereas no such effect is observed in the aorta of diet-induced obese rats [10]. These studies, none of which further characterized the identity of the contractile factor(s) derived from perivascular adipose, suggest a profound heterogeneity in perivascular adipose-dependent regulation of arterial vasoconstriction that may depend on the vascular bed and species studied. Furthermore, perivascular adipose surrounding the murine aorta is highly similar to brown fat and resistant to inflammatory activation in response to a high-fat diet, and therefore differs from other vascular beds [39]. Anatomic heterogeneity might explain the ADCF activity present in murine aorta reported in the present study, which, unlike murine mesenteric resistance arteries or rat aorta [6][8], [10], displays only small adipose-dependent anti-contractile effects under healthy conditions [40].

Obesity results in increased activity of COX-1 and its inducible isoform COX-2 in adipose [42], key enzymes involved in the generation of prostaglandins, prostacyclins and thromboxanes, including the potent vasoconstrictor thromboxane A2 [42]. Different cell types present in perivascular adipose such as adipocytes, endothelial cells, fibroblasts, and immune cells, express COX and thus may contribute to ADCF formation [42]; in particular, adipocytes have been found to express both COX-1 and COX-2 [41]. Cell-specific deletion of COX isoforms might allow further characterization of the cellular source(s) of ADCF activity in perivascular adipose. Of note, both isoform-selective inhibitors for COX-1 and COX-2 were each partially effective in counteracting ADCF activity. The ADCF response contrasts the enhanced EDCF activity in obesity (in arteries devoid of perivascular adipose [12][14], [58], [59]), which is strictly COX-1 dependent [12], [58], [60]. Taken together, obesity appears to involve enhanced activity of both endothelium-derived and perivascular adipose-derived vasoconstrictor prostanoids further lending support to the concept that COX is centrally involved in the enhanced net vasoconstriction observed in obesity in both animals and humans [22], [26].

It is currently not known what mechanisms trigger formation of ADCF in obesity; however, this may be functionally related to or involve local hypoxia. Rapid adipose expansion in obesity, including perivascular adipose, may cause local hypoxia [61], resulting in dysregulated production of adipokines within perivascular adipose [62]. Furthermore, in obesity, hypoxia may also increase non-adipose, i.e. vascular production of vasoconstrictor prostanoids [59]. In agreement with our findings obtained in two different models of obesity, hypoxia similarly reduces anti-contractile properties of perivascular adipose [9]; acute hypoxia even results in transient contractions that are partly COX-dependent [2]. These findings support the concept that in obesity both perivascular adipose and endothelial cells represent sources of COX-derived vasoconstrictor prostanoids, including thromboxane A2, which may act in concert to increase vascular smooth muscle tone. Finally, the discovery of ADCF activity identifies perivascular adipose as a novel regulator of vasoconstriction that may help to explain blood pressure changes in genetically modified mice. For example, deletion of the thromboxane prostanoid (TP) receptor, the main target of vasoconstrictor prostanoids [47], is associated with lower systolic blood pressure than in wild-type mice [63]. This may be due, at least in part, to a lack of contraction via perivascular adipose-derived prostanoids, including thromboxane A2. Moreover, a vasoconstrictor role for perivascular adipose is further supported by data obtained in mice with smooth muscle-specific deletion of PPARγ [64], [65]. These mice are characterized by a complete lack of perivascular adipose and are hypotensive during their resting period [64], [65].

In summary, the present study has identified and characterized an “adipose-derived contracting factor” (ADCF) formed through COX-dependent pathways in perivascular adipose and detected formation of the potent vasoconstrictor thromboxane A2 from perivascular adipose in lean and, to a greater extent, obese mice. The functional activity of this ADCF was shown to contribute to the increased vascular tone in experimental obesity and may also play a role in the increased vascular tone in obese patients [11]. Whether therapeutic countermeasures, such as physical exercise or reducing dietary calorie intake, both of which improve endothelial-dependent vasodilator function [22], [66], might inhibit ADCF activity or increase perivascular adipose-dependent vasodilator capacity, remains to be determined. The recent finding that in obese patients, augmented vasoconstriction can be blocked by a COX-inhibitor [26] suggests that release and activity of ADCF could, at least in part, contribute to the increased vascular smooth muscle tone and thus development of hypertension in obese humans. Pharmacological inhibition of COX-dependent ADCF formation or reducing perivascular adipose mass, secondary to weight reduction, may thus represent novel therapeutic strategies to lower vascular tone and cardiovascular disease risk associated with obesity. Finally, Bailey et al. [67] and FitzGerald and colleagues [68] have demonstrated that COX-derived prostanoids directly contribute to atherosclerosis progression. Thus, the recently reported observation that perivascular adipose aggravates atherosclerosis [69] suggests the involvement of ADCF-dependent mechanisms.

Supporting Information

Figure S1.

Obesity in 3 month-old male GPER0 mice. A, Body weight of 3 month-old male GPER0 mice (, n = 16) and WT controls (CTL, , n = 27). *p = 0.01 vs. CTL. B, Aortic perivascular adipose (PVAT) mass of 3 month-old male GPER0 (, n = 5) and CTL mice (CTL, , n = 5). *p = 0.02 vs. CTL.


Figure S2.

COX inhibition of phenylephrine-induced contractions in vessels of obese mice. Aortic rings with perivascular adipose were obtained from WT mice fed a regular chow (control), GPER0 mice, and WT animals fed a high-fat diet (DIO). Where indicated, rings were treated with the cyclooxygenase inhibitor meclofenamate (Meclo, 1 mmol/L) prior to stimulation. Inset: Area under the curve (AUC) is expressed as arbitrary units (AU). , control, untreated (n = 6); , control, meclofenamate (n = 7); , GPER0, untreated (n = 6); GPER0, meclofenamate, (n = 6); , DIO, untreated (n = 6); , DIO, meclofenamate (n = 6). *p<0.01 vs. untreated vascular rings; †P<0.05 vs. control.


Figure S3.

Cyclooxygenase subtype-specific inhibition of vascular contraction in mice with monogenic obesity. Aortic rings with perivascular adipose were obtained from GPER0 mice and WT mice fed a regular chow (control). Concentration-dependent contractions to serotonin were determined in the presence of selective inhibitors for cyclooxygenase type 1 (SC-560, 300 nmol/L) and type 2 (CAY10404, 100 nmol/L). Inset: Area under the curve (AUC) is expressed as arbitrary units (AU). , control, untreated (n = 6); , control, SC-560 (n = 4); , control, CAY10404 (n = 4); , GPER0, untreated (n = 7); , GPER0, SC-560 (n = 7); GPER0, CAY10404 (n = 6). *p<0.05 vs. untreated vascular rings; †p<0.05 vs. control.


Figure S4.

Cyclooxygenase subtype-specific inhibition of vascular contraction in perivascular adipose-intact aortic rings of mice with diet-induced obesity. Animals were fed a high-fat diet for 24 weeks (DIO) and compared to age-matched mice fed standard chow (control). Concentration-dependent contractions to serotonin were determined in the presence of selective inhibitors for cyclooxygenase type 1 (SC-560, 300 nmol/L) and type 2 (CAY10404, 100 nmol/L). Inset: Area under the curve (AUC) is expressed as arbitrary units (AU). , control, untreated (n = 6); , control, SC-560 (n = 4); , control, CAY10404 (n = 4); , DIO, untreated (n = 7); , DIO, SC-560 (n = 6); , DIO, CAY10404 (n = 5). *p<0.05 vs. untreated vascular rings; †p<0.05 vs. control.


Table S1.

Sets of primers used for amplification of gene-specific cDNA fragments by qPCR. TNFα, tumor necrosis factor α; PPARγ, peroxisome proliferator activated receptor γ; COX, cyclooxygenase.



We thank Dr. Chelin Hu and Daniel F. Cimino for expert technical assistance, Dr. Oliver Baretella for helpful discussions, and Dr. Christian Binggeli for programming and providing FitLab® software.

Author Contributions

Conceived and designed the experiments: MRM MB ERP. Performed the experiments: MRM NCF. Analyzed the data: MRM NCF MB ERP. Wrote the paper: MRM MB ERP.


  1. 1. Ouwens DM, Sell H, Greulich S, Eckel J (2010) The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 14: 2223–2234.
  2. 2. Maenhaut N, Van de Voorde J (2011) Regulation of vascular tone by adipocytes. BMC Med 9: 25.
  3. 3. Gollasch M (2012) Vasodilator signals from perivascular adipose tissue. Br J Pharmacol 165: 633–642.
  4. 4. Eringa EC, Bakker W, van Hinsbergh VW (2012) Paracrine regulation of vascular tone, inflammation and insulin sensitivity by perivascular adipose tissue. Vascul Pharmacol 56: 204–209.
  5. 5. Gao YJ, Takemori K, Su LY, An WS, Lu C, et al. (2006) Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 71: 363–373.
  6. 6. Soltis EE, Cassis LA (1991) Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens A 13: 277–296.
  7. 7. Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, et al. (2002) Periadventitial fat releases a vascular relaxing factor. FASEB J 16: 1057–1063.
  8. 8. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, et al. (2007) Adiponectin is a novel humoral vasodilator. Cardiovasc Res 75: 719–727.
  9. 9. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, et al. (2009) Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 119: 1661–1670.
  10. 10. Ma L, Ma S, He H, Yang D, Chen X, et al. (2010) Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res 33: 446–453.
  11. 11. Lehman SJ, Massaro JM, Schlett CL, O'Donnell CJ, Hoffmann U, et al. (2010) Peri-aortic fat, cardiovascular disease risk factors, and aortic calcification: the Framingham Heart Study. Atherosclerosis 210: 656–661.
  12. 12. Traupe T, Lang M, Goettsch W, Münter K, Morawietz H, et al. (2002) Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 20: 2239–2245.
  13. 13. Traupe T, d'Uscio LV, Muenter K, Morawietz H, Vetter W, et al. (2002) Effects of obesity on endothelium-dependent reactivity during acute nitric oxide synthase inhibition: modulatory role of endothelin. Clin Sci (Lond) 103 Suppl 4813S–15S.
  14. 14. Meyer MR, Amann K, Field AS, Hu C, Hathaway HJ, et al. (2012) Deletion of G protein-coupled estrogen receptor increases endothelial vasoconstriction. Hypertension 59: 507–512.
  15. 15. Furchgott RF, Vanhoutte PM (1989) Endothelium-derived relaxing and contracting factors. FASEB J 3: 2007–2018.
  16. 16. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307: 1625–1630.
  17. 17. Prossnitz ER, Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7: 715–726.
  18. 18. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, et al. (2009) Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 104: 288–291.
  19. 19. Ford J, Hajibeigi A, Long M, Hahner L, Gore C, et al. (2011) GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. J Bone Miner Res 26: 298–307.
  20. 20. Wang C, Dehghani B, Li Y, Kaler LJ, Proctor T, et al. (2009) Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol 182: 3294–3303.
  21. 21. Barton M, Carmona R, Morawietz H, d'Uscio LV, Goettsch W, et al. (2000) Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 35: 329–336.
  22. 22. Barton M, Baretella O, Meyer MR (2012) Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. Br J Pharmacol 165: 591–602.
  23. 23. Cardillo C, Campia U, Iantorno M, Panza JA (2004) Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 43: 36–40.
  24. 24. Ghiadoni L, Penno G, Giannarelli C, Plantinga Y, Bernardini M, et al. (2008) Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. Hypertension 51: 440–445.
  25. 25. Campia U, Tesauro M, Cardillo C (2012) Human obesity and endothelium-dependent responsiveness. Br J Pharmacol 165: 561–573.
  26. 26. Farb MG, Tiwari S, Karki S, Ngo DT, Carmine B, et al.. (2013) Cyclooxygenase inhibition improves endothelial vasomotor dysfunction of visceral adipose arterioles in human obesity. Obesity (Silver Spring): (in press); doi: 10.1002/oby.20505.
  27. 27. Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, et al.. (2013) GPER deficiency in male mice results in insulin resistance, dyslipidemia and a proinflammatory state. Endocrinology August 22 (epub ahead of print) doi: 10.1210/en.2013–1357.
  28. 28. Meyer MR, Field AS, Kanagy NL, Barton M, Prossnitz ER (2012) GPER regulates endothelin-dependent vascular tone and intracellular calcium. Life Sci 91: 623–627.
  29. 29. West DB, Boozer CN, Moody DL, Atkinson RL (1992) Dietary obesity in nine inbred mouse strains. Am J Physiol 262: R1025–1032.
  30. 30. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, et al. (2008) Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 21: 1288–1291.
  31. 31. Mulvany MJ, Halpern W (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19–26.
  32. 32. Baretella O, Xu A, Vanhoutte PM (2013) Acidosis prevents and alkalosis augments endothelium-dependent contractions in mouse arteries. Pflugers Arch July 20 (epub ahead of print) doi: 10.1007/s00424-00013-01323-z.
  33. 33. Ihara M, Ishikawa K, Fukuroda T, Saeki T, Funabashi K, et al. (1992) In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol 20 Suppl 12S11–S14.
  34. 34. Ospina JA, Duckles SP, Krause DN (2003) 17beta-estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. Am J Physiol Heart Circ Physiol 285: H241–H250.
  35. 35. Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 72: 2994–2998.
  36. 36. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
  37. 37. DeLean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97–E102.
  38. 38. Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level—time curve. J Pharmacokinet Biopharm 6: 539–546.
  39. 39. Fitzgibbons TP, Kogan S, Aouadi M, Hendricks GM, Straubhaar J, et al. (2011) Similarity of mouse perivascular and brown adipose tissues and their resistance to diet-induced inflammation. Am J Physiol Heart Circ Physiol 301: H1425–H1437.
  40. 40. Ketonen J, Shi J, Martonen E, Mervaala E (2010) Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57Bl/6 mice. Circ J 74: 1479–1487.
  41. 41. Xu L, Miyoshi H, Nishimura K, Jisaka M, Nagaya T, et al. (2007) Gene expression of isoformic enzymes in arachidonate cyclooxygenase pathway and the regulation by tumor necrosis factor alpha during life cycle of adipocytes. Prostaglandins Other Lipid Mediat 83: 213–218.
  42. 42. Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56: 387–437.
  43. 43. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415.
  44. 44. Rubanyi GM, Vanhoutte PM (1986) Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 250: H822–827.
  45. 45. Li H, Forstermann U (2013) Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 13: 161–167.
  46. 46. Wilcox CS, Pearlman A (2008) Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol Rev 60: 418–469.
  47. 47. Feletou M, Vanhoutte PM (2006) Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 291: H985–H1002.
  48. 48. Aghamohammadzadeh R, Heagerty AM (2012) Obesity-related hypertension: epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue. Ann Med 44 Suppl 1S74–S84.
  49. 49. Kellaway CH, Trethewie ER (1940) The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Quart J Exp Physiol 30: 121–145.
  50. 50. Campbell DH, Nicoll PA (1940) Studies on in vitro anaphylaxis and release of an active non-histamine material from sensitized guinea pig lung. J Immunol 39: 103–112.
  51. 51. Berry PA, Collier HO (1964) Bronchoconstrictor action and antagonism of a slow-reacting substance from anaphylaxis of guinea-pig isolated lung. Br J Pharmacol Chemother 23: 201–216.
  52. 52. Ferreira SH, Vargaftig BB (1974) Inhibition by non-steroid anti-inflammatory agents of rabbit aorta contracting activity generated in blood by slow reacting substance C. Br J Pharmacol 50: 543–551.
  53. 53. Gryglewski R, Vane JR (1972) The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol 45: 37–47.
  54. 54. Piper PJ, Vane JR (1969) Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 223: 29–35.
  55. 55. Gryglewski R, Vane JR (1972) The generation from arachidonic acid of rabbit aorta contracting substance (RCS) by a microsomal enzyme preparation which also generates prostaglandins. Br J Pharmacol 46: 449–457.
  56. 56. Nijkamp FP, Flower RJ, Moncada S, Vane JR (1976) Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids. Nature 263: 479–482.
  57. 57. De Mey JG, Vanhoutte PM (1982) Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 51: 439–447.
  58. 58. Smith AD, Dorrance AM (2006) Arachidonic acid induces augmented vasoconstriction via cyclooxygenase 1 in the aorta from rats fed a high-fat diet. Prostaglandins Leukot Essent Fatty Acids 75: 43–49.
  59. 59. Goodwill AG, James ME, Frisbee JC (2008) Increased vascular thromboxane generation impairs dilation of skeletal muscle arterioles of obese Zucker rats with reduced oxygen tension. Am J Physiol Heart Circ Physiol 295: H1522–H1528.
  60. 60. Tang EH, Ku DD, Tipoe GL, Feletou M, Man RY, et al. (2005) Endothelium-dependent contractions occur in the aorta of wild-type and COX2-/- knockout but not COX1-/- knockout mice. J Cardiovasc Pharmacol 46: 761–765.
  61. 61. Xu J, Xiang Q, Lin G, Fu X, Zhou K, et al. (2012) Estrogen improved metabolic syndrome through down-regulation of VEGF and HIF-1alpha to inhibit hypoxia of periaortic and intra-abdominal fat in ovariectomized female rats. Mol Biol Rep 39: 8177–8185.
  62. 62. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, et al. (2007) Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56: 901–911.
  63. 63. Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, et al. (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102: 1994–2001.
  64. 64. Chang L, Milton H, Eitzman DT, Chen YE (2013) Paradoxical roles of perivascular adipose tissue in atherosclerosis and hypertension. Circ J 77: 11–18.
  65. 65. Chang L, Villacorta L, Li R, Hamblin M, Xu W, et al. (2012) Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-gamma deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation 126: 1067–1078.
  66. 66. Barton M (2013) Prevention and endothelial therapy of coronary artery disease. Curr Opin Pharmacol 13: 226–241.
  67. 67. Bailey JM, Makheja AN, Butler J, Salata K (1979) Anti-inflammatory drugs in experimental atherosclerosis. Part 4. Inhibition of atherosclerosis in vivo and thromboxane synthesis and platelet aggregation in vitro. Atherosclerosis 32: 195–203.
  68. 68. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA (2001) Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A 98: 3358–3363.
  69. 69. Ohman MK, Luo W, Wang H, Guo C, Abdallah W, et al. (2011) Perivascular visceral adipose tissue induces atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 219: 33–39.